Tourmaline Bio's Q2 2025 was marked by the successful topline results of the TRANQUILITY trial and a widening net loss driven by increased R&D investment. The company remains well-capitalized to advance its pipeline through 2027.

Tourmaline Bio announced its financial results for the first quarter of 2025, with a net loss of $22.97 million. The company's Phase 2 TRANQUILITY trial for pacibekitug remains on track for topline data readout in the second quarter of 2025, and cash, cash equivalents, and investments of $275.3 million are expected to provide a cash runway into the second half of 2027.

Tourmaline Bio reported a net loss of $22.2 million for Q4 2024, with cash, cash equivalents, and investments totaling $294.9 million, providing a cash runway into the second half of 2027. The company over-enrolled its Phase 2 TRANQUILITY trial and strengthened its Cardiovascular Scientific Advisory Board.

Tourmaline Bio reported a net loss of $20.2 million for the third quarter of 2024. Cash, cash equivalents and investments were $314.4 million as of September 30, 2024, providing cash runway into 2027.

Tourmaline Bio reported its second quarter 2024 financial results. The company's cash, cash equivalents and investments were $334.4 million as of June 30, 2024, providing cash runway into 2027. First patient was dosed in May 2024 in Phase 2 TRANQUILITY trial. Company is on track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease (TED) in the second half of 2024.

Tourmaline Bio reported a net loss of $13.3 million for the first quarter of 2024, with cash, cash equivalents, and investments totaling $350.3 million, expected to provide cash runway into 2027. The company progressed its TOUR006 clinical programs, including initiating a Phase 2 trial in ASCVD and expanding its Thyroid Eye Disease clinical development plan.

Tourmaline Bio reported a net loss of $12.9 million for Q4 2023, with cash, cash equivalents, and investments totaling $203.0 million as of December 31, 2023. Research and development expenses were $8.0 million, while general and administrative expenses amounted to $6.9 million for the quarter. The company anticipates its current cash runway will extend into 2027.

Talaris Therapeutics reported a net loss of $19.0 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $193.9 million as of September 30, 2022, providing an expected runway through 2024. Enrollment continues in the Phase 3 FREEDOM-1 trial.

Talaris Therapeutics reported a net loss of $14.2 million for Q4 2021 and finished the quarter with $244 million in cash, cash equivalents and marketable securities. The company continues to advance its clinical programs, including the Phase 3 FREEDOM-1 trial and the newly initiated Phase 2 FREEDOM-2 and FREEDOM-3 trials.

Talaris Therapeutics announced its Q3 2021 financial results, reporting a net loss of $12.9 million, or $0.32 per share. The company highlighted the initial clinical update from its Phase 3 FREEDOM-1 trial and the initiation of the Phase 2 FREEDOM-2 clinical trial.

Talaris Therapeutics reported its Q2 2021 financial results, highlighting progress with FREEDOM-1 trial and plans for FREEDOM-2 and FREEDOM-3 trials. The company's cash, cash equivalents, and marketable securities totaled $266.2 million, expected to fund operations into 2025.